Delivery Order SPE2DB20D3103-SPE2DB25FQ3B7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,054.35 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of April 22, 2025. This competitive, non-set-aside award reflects the agency's procurement of critical pharmaceutical supplies for military and federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a key vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $2,427.99 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a firm fixed-price delivery under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting...
- The Defense Logistics Agency awarded a $1,003.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of July 28, 2025. This contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle active through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,380.61 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency issued a delivery order valued at $2,313.78 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $4,479.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 20, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government....
- The Defense Logistics Agency awarded a delivery order valued at $1,092.72 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued on September 8, 2025, and represents a firm fixed-price pharmaceutical supply transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a primary pharmaceutical...
- The Defense Logistics Agency awarded a $12,030.04 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,827.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of September 15, 2025. This non-set-aside contract was competitively awarded on September 12, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ3B7Delivery Order
The Defense Logistics Agency awarded a $1,959.32 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of September 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through its extensive contracts with the Defense Logistics Agency Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's ability to fulfill this insulin procurement demonstrates its role as a key provider within the federal pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/15/25 |